# A Double-blind, Randomized Conversion to Monotherapy Study to Evaluate the Efficacy and Safety of Brivaracetam in Subjects (≥ 16 to 75 Years Old) With Partial Onset Seizures

> **NCT00698581** · PHASE3 · TERMINATED · sponsor: **UCB Pharma** · enrollment: 88 (actual)

## Conditions studied

- Epilepsy

## Interventions

- **DRUG:** Brivaracetam
- **DRUG:** Brivaracetam

## Key facts

- **NCT ID:** NCT00698581
- **Lead sponsor:** UCB Pharma
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2008-08
- **Primary completion:** 2010-01
- **Final completion:** 2010-02
- **Target enrollment:** 88 (ACTUAL)
- **Why stopped:** An interim analysis revealed the study was unlikely to attain a positive outcome for the efficacy analysis. No safety concerns were detected.
- **Last updated:** 2018-07-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00698581

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00698581, "A Double-blind, Randomized Conversion to Monotherapy Study to Evaluate the Efficacy and Safety of Brivaracetam in Subjects (≥ 16 to 75 Years Old) With Partial Onset Seizures". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00698581. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*